Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Nasus Pharma (NSRX) will present at the H.C.

Rhea-AI Summary

Nasus Pharma (NSRX) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14-16, 2026. The company’s presentation will be available on demand from the conference website starting September 11, 2026. CEO Brendan O’Grady and CFO Eyal Rubin will also hold one-on-one meetings with investors during the event.

Key Figures

Conference dates: September 14-16, 2026 Presentation availability: September 11, 2026

Conference dates

September 14-16, 2026

H.C. Wainwright Global Investment Conference

Presentation availability

September 11, 2026

On-demand presentation release

Key Terms

anaphylaxis, intranasal

2 terms

anaphylaxis medical

"intranasal epinephrine treatment for Type I allergic reactions, including anaphylaxis"

Anaphylaxis is a sudden, severe allergic reaction in which the body's defense system overreacts to a trigger (like a drug, food, or insect sting), causing widespread symptoms such as difficulty breathing, low blood pressure, and shock; it can be life‑threatening without prompt treatment. Investors care because anaphylaxis risks can affect a drug or product's safety profile, regulatory approval, liability exposure and market acceptance—similar to a sprinkler system going off and damaging the whole house rather than just one room.

intranasal medical

"development of innovative intranasal products"

Administration or delivery of a drug or vaccine through the nose, typically via a spray or drops that are absorbed by the nasal tissues. For investors, intranasal products can matter because they often offer easier, needle-free use, faster onset of effect, and potential cost or compliance advantages that can widen a product’s market and affect regulatory review, manufacturing complexity, and commercial prospects — similar to how a convenient app can outsell a clunky desktop program.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TEL AVIV, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the Company’s management team will participate and present in the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-16, 2026 in New York, NY, at the Lotte New York Palace hotel.

The Company’s presentation will be available on demand from the conference website beginning Friday, September 11, 2026. Brendan O’Grady, Chief Executive Officer, and Eyal Rubin, Chief Financial Officer, will be available for one-on-one meetings with investors throughout the conference. Investors interested in arranging a meeting can register for the conference here or should contact their H.C. Wainwright representative.

About Nasus Pharma

Nasus Pharma Ltd. (NYSE: NSRX) is a biopharmaceutical company advancing innovative intranasal therapies through its proprietary intranasal powder technology platform. The Company's lead product candidate, NS002, is being developed as an intranasal epinephrine treatment for Type I allergic reactions, including anaphylaxis. In addition to NS002, Nasus is leveraging its proprietary technology platform to develop a growing pipeline of differentiated intranasal product candidates designed to provide rapid, reliable and patient-friendly drug delivery across multiple therapeutic areas.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the negative of these words, similar expressions or variations of such words are intended to identify forward-looking statements. For example, Nasus Pharma is using forward-looking statements in this press release when it discusses: statements regarding the Company's strategy to commercialize NS002 and unlocking its commercial potential; advancing the Company’s pipeline and  future business development initiatives, maximizing the value of its proprietary Nasax intranasal technology platform; the next phase of Nasus Pharma’s growth; the Company advancing NS002 toward a pivotal trial in the fourth quarter of 2026 and topline data readout the first quarter of 2027; the increasing strategic focus on pre-commercial planning; the opportunity NS002 presents to address a significant unmet medical need; the believe that the Nasus portfolio represents a significant value generation opportunity; and the potential applications and promise of the Company’s proprietary intranasal technology platform. These forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to update or revise these forward-looking statements except as required by applicable law.

Company Contact
Nasus Pharma Ltd.
info@nasuspharma.com

Investor Contact
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com

FAQ

How can investors schedule one-on-one meetings with Nasus Pharma at the conference?

Investors interested in arranging a one-on-one meeting with Nasus Pharma during the conference can register for the event through the conference website or contact their H.C. Wainwright representative.

When and where will Nasus Pharma’s conference presentation be available?

The company’s presentation will be available on demand from the H.C. Wainwright 28th Annual Global Investment Conference website beginning Friday, September 11, 2026, in conjunction with the event held at the Lotte New York Palace hotel in New York.